Infinite dimensional differential games with hybrid controls

A two-person zero-sum infinite dimensional differential game of infinite duration with discounted payoff involving hybrid controls is studied. The minimizing player is allowed to take continuous, switching and impulse controls whereas the maximizing player is allowed to take continuous and switching controls. By taking strategies in the sense of Elliott--Kalton, we prove the existence of value and characterize it as the unique viscosity solution of the associated system of quasi-variational inequalities

SINONASAL VERRUCOUS CARCINOMA Case series and review of literature

Verrucous carcinoma is a low grade malignancy and is a variant of squamous cell carcinoma. It is a rare tumour of the Sino nasal tract. The neoplasm occurs in older people usually in the seventh or eighth decade of life. Our cases were sinonasal in origin and patients affected were young.

Patient Choice for Older People in English NHS Primary Care: Theory and Practice

In the English National Health Service (NHS), patients are now expected to choose the time and place of treatment and even choose the actual treatment. However, the theory on which patient choice is based and the implementation of patient choice are controversial. There is evidence to indicate that attitudes and abilities to make choices are relatively sophisticated and not as straightforward as policy developments suggest. In addition, and surprisingly, there is little research on whethermaking individual choices about care is regarded as a priority by the largest NHS patient group and the single largest group for most GPs—older people.This conceptual paper examines the theory of patient choice concerning accessing and engaging with healthcare provision and reviews existing evidence on older people and patient choice in primary care

Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke

Stroke outcome is worsened by the infiltration of inflammatory immune cells into ischemic brains. Our recent study demonstrated that PD-L1- and to a lesser extent PD-L2-deficient mice had smaller brain infarcts and fewer brain-infiltrating cells vs. wild-type (WT) mice, suggesting a pathogenic role for PD-ligands in experimental stroke. We sought to ascertain PD-L1 and PD-L2-expressing cell types that affect T-cell activation, post-stroke in the context of other known co-stimulatory molecules. Thus, cells from male WT and PD-L-deficient mice undergoing 60 min of middle cerebral artery occlusion (MCAO) followed by 96 h of reperfusion were treated with neutralizing antibodies to study co-stimulatory and co-inhibitory interactions between CD80, cytotoxic T-lymphocyte antigen-4 (CTLA-4), PD-1, and PD-Ls that regulate CD8(+) and CD4(+) T-cell activation. We found that antibody neutralization of PD-1 and CTLA-4 signaling post-MCAO resulted in higher proliferation in WT CD8(+) and CD4(+) T-cells, confirming an inhibitory role of PD-1 and CTLA-4 on T-cell activation. Also, CD80/CD28 interactions played a prominent regulatory role for the CD8(+) T-cells and the PD-1/PD-L2 interactions were dominant in controlling the CD4(+) T-cell responses in WT mice after stroke. A suppressive phenotype in PD-L1-deficient mice was attributed to CD80/CTLA-4 and PD-1/PD-L2 interactions. PD-L2 was crucial in modulating CD4(+) T-cell responses, whereas PD-L1 regulated both CD8(+) and CD4(+) T-cells. To establish the contribution of PD-L1 and PD-L2 on regulatory B-cells (Bregs), infarct volumes were evaluated in male PD-L1- and PD-L2-deficient mice receiving IL-10(+) B-cells 4h post-MCAO. PD-L2- but not PD-L1-deficient recipients of IL-10(+) B-cells had markedly reduced infarct volumes, indicating a regulatory role of PD-L2 on Bregs. These results imply that PD-L1 and PD-L2 differentially control induction of T- and Breg-cell responses after MCAO, thus suggesting that selective targeting of PD-L1 and PD-L2 might represent a valuable therapeutic strategy in stroke

Searching Drug Targets for Microbes Using Nitrogen Heterocycles

Not availabl

Role of scavenger receptor MARCO in particle uptake and lung inflammation

Alveolar macrophages (AM) form the first line of defense against chronic inflammation caused by occupational exposure to environmental particulates such as crystalline silica (CSiO2). The chronic inflammatory process triggered by CSiO2 is known to culminate into a fibrotic response called silicosis in the human lungs. Previous studies have indicated the role of membrane glycoproteins called scavenger receptors in binding of environmental particles. The scavenger receptors are classified into different classes (A-H) based on their structure and function. Class A scavenger receptors are critical in uptake of variety of ligands such as bacteria, acetylated lipoproteins and are typically found on macrophages, dendritic and epithelial cells. One of the members of this family is Macrophage receptor with collagenous structure (MARCO). Recent studies have focused on analyzing the interaction between MARCO and inorganic particles such as CSiO2 and titanium dioxide (TiO2). Both in vivo and in vitro binding studies have identified MARCO as a key receptor in CSiO2 uptake and subsequent cytotoxicity in AM from C57Bl/6 mice. Further in vitro studies using a transfected cell line revealed that the 100 amino acid residues long cysteine-rich (SRCR) domain at the C-terminal end of MARCO is required for binding of inorganic particles such as CSiO2, TiO2 and amorphous silica (ASiO2). Moreover, individual particles bind to SRCR domain of MARCO with unique differences and have varying requirements with respect to need for divalent cations. Our studies demonstrate that physiological absence of MARCO in C57Bl/6 mice leads to a more robust inflammatory response following CSiO2 exposure as compared to wild-type mice. The results suggest that diminished clearance of CSiO2 particles from the MARCO-/- lungs exacerbates the lung inflammation. These findings demonstrate that the involvement of different regions of SRCR domain may distinguish downstream events following particle binding. Taken together, these data establish the role of MARCO in uptake of various inorganic particles and elucidate the protective role of MARCO in CSiO2-induced lung inflammation

RCC1-dependent activation of Ran accelerates cell cycle and DNA repair, inhibiting DNA damage–induced cell senescence

© The Author(s), 2016. This article is distributed under the terms of the Creative Commons Attribution License. The definitive version was published in Molecular Biology of the Cell 27 (2016): 1346-1357, doi:10.1091/mbc.E16-01-0025.The coordination of cell cycle progression with the repair of DNA damage supports the genomic integrity of dividing cells. The function of many factors involved in DNA damage response (DDR) and the cell cycle depends on their Ran GTPase–regulated nuclear–cytoplasmic transport (NCT). The loading of Ran with GTP, which is mediated by RCC1, the guanine nucleotide exchange factor for Ran, is critical for NCT activity. However, the role of RCC1 or Ran⋅GTP in promoting cell proliferation or DDR is not clear. We show that RCC1 overexpression in normal cells increased cellular Ran⋅GTP levels and accelerated the cell cycle and DNA damage repair. As a result, normal cells overexpressing RCC1 evaded DNA damage–induced cell cycle arrest and senescence, mimicking colorectal carcinoma cells with high endogenous RCC1 levels. The RCC1-induced inhibition of senescence required Ran and exportin 1 and involved the activation of importin β–dependent nuclear import of 53BP1, a large NCT cargo. Our results indicate that changes in the activity of the Ran⋅GTP–regulated NCT modulate the rate of the cell cycle and the efficiency of DNA repair. Through the essential role of RCC1 in regulation of cellular Ran⋅GTP levels and NCT, RCC1 expression enables the proliferation of cells that sustain DNA damage.P.C., K.H., Y.P., J.-Q.C., M.A.H., S.K., and P.K. were supported by the Intramural Research Program of the Center for Cancer Research, NCI. D.O. and E.T. were supported by National Institutes of Health grant R01 GM071522